University of Minnesota. Driven to Discover.
Of $1.6 billion appropriated, $412 million has been targeted to 131 projects.
Experts made more recommendations about fractional IPV dosing and also discussed issued related to cholera, Ebola, and diphtheria.
About 4% of patients traveled, a potential target for curbing disease spread.
The phase 2 trials will enroll more than 5,000 adults and kids in Guinea and Liberia.
About 7.5% of close contacts tested positive, while another study dissected convalescent plasma use.
"I would view the results . . . in an optimistic light," said lead author Richard Davey after the drug showed more than 90% efficacy.
The move signals the end of enhanced screening in the United States related to West Africa's Ebola outbreak.
The WHO also warned of the risk of flare-ups due to ligering virus in some survivors, a threat it says will decline with time.
Also, a short report notes gender differences during the outbreak, such as higher survival in females.
Social networks, though, were strong in poorer areas, which helped with disease control.
Get CIDRAP news and other free newsletters.
Sign up now»
Unrestricted financial support provided by
Grant support for ASP provided by
Become an underwriter»
CIDRAP - Center for Infectious Disease Research and PolicyOffice of the Vice President for Research, University of Minnesota, Minneapolis, MN
© 2020 Regents of the University of Minnesota. All rights reserved.The University of Minnesota is an equal opportunity educator and employer.